4,619 reports of this reaction
10.6% of all CLOBAZAM reports
#1 most reported adverse reaction
SEIZURE is the #1 most commonly reported adverse reaction for CLOBAZAM, manufactured by Lundbeck Pharmaceuticals LLC. There are 4,619 FDA adverse event reports linking CLOBAZAM to SEIZURE. This represents approximately 10.6% of all 43,741 adverse event reports for this drug.
Patients taking CLOBAZAM who experience seizure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEIZURE is a frequently reported adverse event for CLOBAZAM, accounting for a significant proportion of all reports.
In addition to seizure, the following adverse reactions have been reported for CLOBAZAM:
The following drugs have also been linked to seizure in FDA adverse event reports:
SEIZURE has been reported as an adverse event in 4,619 FDA reports for CLOBAZAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEIZURE accounts for approximately 10.6% of all adverse event reports for CLOBAZAM, making it one of the most commonly reported side effect.
If you experience seizure while taking CLOBAZAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.